Altimmune Inc.

11.64-0.1100-0.94%Vol 2.07M1Y Perf -27.91%
Jun 28th, 2022 16:00 DELAYED
BID11.17 ASK11.88
Open11.54 Previous Close11.75
Pre-Market- After-Market11.64
 - -  - -%
Target Price
26.40 
Analyst Rating
Strong Buy 1.00
Potential %
126.80 
Finscreener Ranking
★★★★+     56.64
Insiders Trans % 3/6/12 mo.
100/33/33 
Value Ranking
★★★+     53.45
Insiders Value % 3/6/12 mo.
100/-89/-89 
Growth Ranking
★★+     48.88
Insiders Shares Cnt. % 3/6/12 mo.
100/-86/-86 
Income Ranking
 —    -
Price Range Ratio 52W %
58.15 
Earnings Rating
Strong Buy
Market Cap503.07M 
Earnings Date
9th Aug 2022
Alpha-0.01 Standard Deviation0.42
Beta1.43 

Today's Price Range

10.8111.73

52W Range

3.8317.26

5 Year PE Ratio Range

-4.201.20

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
26.07%
1 Month
133.60%
3 Months
89.21%
6 Months
34.29%
1 Year
-27.91%
3 Years
393.70%
5 Years
-88.10%
10 Years
-75.27%

TickerPriceChg.Chg.%
ALT11.64-0.1100-0.94
AAPL137.44-4.2200-2.98
GOOG2 251.43-81.0200-3.47
MSFT256.48-8.4100-3.17
XOM91.502.47002.77
WFC40.18-0.0600-0.15
JNJ176.94-5.1800-2.84
FB196.640.99000.51
GE65.88-0.8300-1.24
JPM115.82-0.5600-0.48
Financial StrengthValueIndustryS&P 500US Markets
9.70
10.00
0.01
0.01
-1 825.50
Leverage Ratio 1.10
ProfitabilityValueIndustryS&P 500US Markets
-
-2 818.80
-2 802.30
-534.50
-
RevenueValueIndustryS&P 500US Markets
3.60M
0.08
-20.44
-9.55
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.57-0.4422.81
Q04 2021-0.64-0.4923.44
Q03 2021-0.36-0.81-125.00
Q02 2021-0.44-0.409.09
Q01 2021-0.39-0.382.56
Q04 2020-0.84-0.1779.76
Q03 2020-0.92-0.5441.30
Q02 2020-0.29-0.94-224.14
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.4522.41Positive
9/2022 QR-0.4922.22Positive
12/2022 FY-1.9019.83Positive
12/2023 FY-1.9818.18Positive
Next Report Date9th Aug 2022
Estimated EPS Next Report-0.45
Estimates Count4
EPS Growth Next 5 Years %-
Volume Overview
Volume2.07M
Shares Outstanding43.22K
Shares Float38.37M
Trades Count20.72K
Dollar Volume23.28M
Avg. Volume2.28M
Avg. Weekly Volume3.20M
Avg. Monthly Volume2.45M
Avg. Quarterly Volume1.20M

Altimmune Inc. (NASDAQ: ALT) stock closed at 11.75 per share at the end of the most recent trading day (a 14.19% change compared to the prior day closing price) with a volume of 4.00M shares and market capitalization of 503.07M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 43 people. Altimmune Inc. CEO is Vipin K. Garg.

The one-year performance of Altimmune Inc. stock is -27.91%, while year-to-date (YTD) performance is 28.28%. ALT stock has a five-year performance of -88.1%. Its 52-week range is between 3.83 and 17.26, which gives ALT stock a 52-week price range ratio of 58.15%

Altimmune Inc. currently has a PE ratio of -4.30, a price-to-book (PB) ratio of 2.41, a price-to-sale (PS) ratio of 140.87, a price to cashflow ratio of 0.10, a PEG ratio of 2.32, a ROA of -44.67%, a ROC of -46.85% and a ROE of -48.69%. The company’s profit margin is -%, its EBITDA margin is -2 802.30%, and its revenue ttm is $3.60 Million , which makes it $0.08 revenue per share.

Of the last four earnings reports from Altimmune Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.45 for the next earnings report. Altimmune Inc.’s next earnings report date is 09th Aug 2022.

The consensus rating of Wall Street analysts for Altimmune Inc. is Strong Buy (1), with a target price of $26.4, which is +126.80% compared to the current price. The earnings rating for Altimmune Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Altimmune Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Altimmune Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 24.14, ATR14 : 1.01, CCI20 : 134.68, Chaikin Money Flow : 0.39, MACD : 1.43, Money Flow Index : 92.57, ROC : 84.46, RSI : 76.58, STOCH (14,3) : 95.95, STOCH RSI : 1.00, UO : 70.80, Williams %R : -4.05), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Altimmune Inc. in the last 12-months were: David J. Drutz (Buy at a value of $13 400), David J. Drutz (Option Excercise at a value of $502), Klaus O. Schafer (Option Excercise at a value of $526), M. Scot Roberts (Option Excercise at a value of $0), Matthew Scott Harris (Option Excercise at a value of $57 639), Matthew Scott Harris (Sold 30 000 shares of value $225 600 ), Vipin K. Garg (Option Excercise at a value of $0)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
4 (100.00 %)
5 (100.00 %)
5 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Altimmune Inc.

Altimmune Inc is a United States-based clinical-stage immunotherapeutic biotechnology company. It is involved in the business of developing products that engage, stimulate and improve immune responses for the prevention and treatment of liver diseases. The firm's product candidates include NasoVAX, HepTcell, SparVax-L, and NasoShield. It also develops platform technologies such as RespirVec and Densigen. The company generates its revenue from cost plus fee contracts and fixed-price contracts.

CEO: Vipin K. Garg

Telephone: +1 240 654-1450

Address: 910 Clopper Road, Gaithersburg 20878, MD, US

Number of employees: 43

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

64%36%

Bearish Bullish

66%34%

Bearish Bullish

66%34%

TipRanks News for ALT

Wed, 01 Jun 2022 04:35 GMT Analysts Offer Insights on Healthcare Companies: Altimmune (ALT) and OrthoPediatrics (KIDS)

- TipRanks. All rights reserved.

Tue, 17 May 2022 10:15 GMT Analysts Offer Insights on Healthcare Companies: Celsion (CLSN), Altimmune (ALT) and Albireo Pharma (ALBO)

- TipRanks. All rights reserved.

Tue, 17 May 2022 04:05 GMT Analysts Offer Insights on Healthcare Companies: Align Tech (ALGN), Altimmune (ALT) and Pear Therapeutics (PEAR)

- TipRanks. All rights reserved.

Tue, 03 May 2022 00:16 GMT Analysts Are Bullish on These Healthcare Stocks: Altimmune (ALT), AbbVie (ABBV)

- TipRanks. All rights reserved.

Thu, 28 Apr 2022 19:05 GMT Altimmune (ALT) Receives a Buy from B.Riley Financial

- TipRanks. All rights reserved.

Tue, 12 Apr 2022 01:15 GMT Altimmune (ALT) Received its Third Buy in a Row

- TipRanks. All rights reserved.

Tue, 22 Mar 2022 10:15 GMT Analysts Top Healthcare Picks: Altimmune (ALT), Mersana Therapeutics (MRSN)

- TipRanks. All rights reserved.

Wed, 16 Mar 2022 12:57 GMT Analysts Top Healthcare Picks: Altimmune (ALT), Jazz Pharmaceuticals (JAZZ)

- TipRanks. All rights reserved.

Thu, 13 Jan 2022 16:36 GMT Analysts Have Conflicting Sentiments on These Healthcare Companies: Orthofix (OFIX), Altimmune (ALT) and Bicycle Therapeutics (BCYC)

- TipRanks. All rights reserved.

News

Stocktwits